/
AMIX
$5.84+$0.12 (+2.10%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.1M
1M shares
52-week range
$4.20 – $55.44
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
12.98%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2123.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $12.0K |
| Gross profit | $0 | $0 | $0 | $0 | −$12.0K |
| Gross margin | — | — | — | — | — |
| R&D | $4.1K | $745.0K | $2.2M | $4.7M | $7.1M |
| Operating income | −$13.6M | −$2.0M | −$12.0M | −$11.6M | −$17.0M |
| EBITDA | −$13.6M | −$2.0M | −$15.3M | −$11.1M | −$17.0M |
| Net income | −$13.3M | −$2.0M | −$15.4M | −$11.4M | −$16.7M |
| Net margin | — | — | — | — | — |
| EPS (diluted) | -14.91 | -2.31 | -442.89 | -135.66 | -48.72 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $0 | $-22.68 | $-22.68–$-22.68 | 1 |
| 2028 | $900000 | $-19.53 | $-19.53–$-19.53 | 1 |
| 2029 | $2M | $-17.43 | $-17.43–$-17.43 | 1 |
| 2030 | $12M | $-12.39 | $-12.39–$-12.39 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$18.44
Price
$5.84
Implied upside
+216%
Peer comparison
Autonomix Medical, Inc. Common Stock
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
www.autonomix.com- Employees
- 11
- IPO / List date
- Jan 29, 2024
- HQ
- THE WOODLANDS, TX
Held by traders on TradeandTell
No one on the platform currently holds AMIX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AMIX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-24 | 1-for-21reverse |
| 2024-10-25 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded AMIX yet.
